Full Text Journal Articles by
Author Kazuki Maesaka

Advertisement

Find full text journal articles








Efficacy of Ramucirumab Versus Sorafenib as Subsequent Treatment for Hepatocellular Carcinoma.

Kazuki Maesaka, Ryotaro Sakamori, Ryoko Yamada, Yuki Tahata, Kazuyoshi Ohkawa, Masahide Oshita, Shinji Tamura, Hideki Hagiwara, Eiji Mita, Takayuki Yakushijin, Masami Inada, Takahiro Kodama, Hayato Hikita, Tomohide Tatsumi, Tetsuo Takehara,

<h4>Background/aim</h4>The present study aimed to examine the therapeutic efficacy of ramucirumab compared with that of sorafenib as subsequent systemic therapy for patients with hepatocellular carcinoma (HCC) and serum α-fetoprotein (AFP) levels ≥400 ng/ml.<h4>Patients and methods</h4>In our prospectively registered, real-world cohort, 13 and 11 patients treated with ramucirumab or sorafenib, respectively, ... Read more >>

Anticancer Res (Anticancer research)
[2021, 41(4):2187-2192]

Cited: 0 times

View full text PDF listing >>



Clinical course of hepatitis C virus-positive patients with decompensated liver cirrhosis in the era of direct-acting antiviral treatment.

Kazuki Maesaka, Ryotaro Sakamori, Ryoko Yamada, Yuki Tahata, Masahide Oshita, Hideki Hagiwara, Mitsuru Sakakibara, Shinji Tamura, Naoki Hiramatsu, Masami Inada, Sadaharu Iio, Toshifumi Ito, Takayuki Yakushijin, Yoshinori Doi, Takahiro Kodama, Hayato Hikita, Tomohide Tatsumi, Tetsuo Takehara,

<h4>Aim</h4>The aim of the present study was to investigate the clinical course in hepatitis C virus (HCV)-positive patients with decompensated liver cirrhosis after direct-acting antivirals (DAAs) have been used for HCV infection.<h4>Methods</h4>This multicenter study prospectively analyzed a registered cohort composed of 73 HCV-positive patients with decompensated cirrhosis who attended our ... Read more >>

Hepatol Res (Hepatology research : the official journal of the Japan Society of Hepatology)
[2021, 51(5):517-527]

Cited: 2 times

View full text PDF listing >>



Advertisement

ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma.

Yuta Myojin, Takahiro Kodama, Kazuki Maesaka, Daisuke Motooka, Yu Sato, Satoshi Tanaka, Yuichi Abe, Kazuyoshi Ohkawa, Eiji Mita, Yoshito Hayashi, Hayato Hikita, Ryotaro Sakamori, Tomohide Tatsumi, Ayumu Taguchi, Hidetoshi Eguchi, Tetsuo Takehara,

<h4>Purpose</h4>Hepatocellular carcinoma (HCC) is characterized by high intertumor heterogeneity of genetic drivers. Two multitarget tyrosine kinase inhibitors (TKI), lenvatinib and sorafenib, are used as standard-of-care chemotherapeutics in patients with advanced HCC, but a stratification strategy has not been established because of a lack of efficacious biomarkers. Therefore, we sought biomarkers ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2021, 27(4):1150-1161]

Cited: 5 times

View full text PDF listing >>



Lower Serum Sodium Levels Are Associated with the Therapeutic Effect of Sorafenib on Hepatocellular Carcinoma.

Tadashi Kegasawa, Ryotaro Sakamori, Kazuki Maesaka, Ryoko Yamada, Yuki Tahata, Ayako Urabe, Takahiro Kodama, Hayato Hikita, Kazuho Imanaka, Kazuyoshi Ohkawa, Naoki Hiramatsu, Masahide Oshita, Yukinori Yamada, Masami Inada, Takayuki Yakushijin, Yasuharu Imai, Tomohide Tatsumi, Tetsuo Takehara,

<h4>Background and aim</h4>Although the serum sodium level has been reported to be a prognostic and predictive marker for the therapeutic effects of lung cancer and renal cell carcinoma treated with molecular targeted therapy, the serum sodium level has not been investigated in hepatocellular carcinoma (HCC) patients treated with sorafenib. The ... Read more >>

Dig Dis Sci (Digestive diseases and sciences)
[2021, 66(5):1720-1729]

Cited: 0 times

View full text PDF listing >>



Initial treatment response to transarterial chemoembolization as a predictive factor for Child-Pugh class deterioration prior to refractoriness in hepatocellular carcinoma.

Kazuki Maesaka, Ryotaro Sakamori, Ryoko Yamada, Yuki Tahata, Yasuharu Imai, Masahide Oshita, Kazuyoshi Ohkawa, Takahiro Kodama, Hayato Hikita, Tomohide Tatsumi, Tetsuo Takehara,

AIM:Repeated transarterial chemoembolization (TACE) for intermediate-stage hepatocellular carcinoma (HCC) eventually leads to either deteriorated hepatic reserve or TACE refractoriness. Switching to molecular targeted agents after TACE requires preservation of hepatic reserve. This study aimed to investigate the predictive factors associated with early deterioration of hepatic reserve by repeated TACE prior ... Read more >>

Hepatol Res (Hepatology research : the official journal of the Japan Society of Hepatology)
[2020, 50(11):1275-1283]

Cited: 0 times

View full text PDF listing >>



Therapeutic efficacy of lenvatinib in hepatocellular carcinoma patients with portal hypertension.

Kazuki Maesaka, Ryotaro Sakamori, Ryoko Yamada, Ayako Urabe, Yuki Tahata, Masahide Oshita, Kazuyoshi Ohkawa, Eiji Mita, Hideki Hagiwara, Shinji Tamura, Toshifumi Ito, Takayuki Yakushijin, Sadaharu Iio, Takahiro Kodama, Hayato Hikita, Tomohide Tatsumi, Tetsuo Takehara,

<h4>Aim</h4>Preserved liver function may be an important factor affecting therapeutic efficacy in hepatocellular carcinoma patients treated with lenvatinib, but not all patients can be treated while preserving liver function. This study evaluated the therapeutic efficacy of lenvatinib in patients with poor liver function with and without portal hypertension.<h4>Methods</h4>This prospectively registered ... Read more >>

Hepatol Res (Hepatology research : the official journal of the Japan Society of Hepatology)
[2020, 50(9):1091-1100]

Cited: 0 times

View full text PDF listing >>



Hypovascular hepatic nodules as a predictive factor for transcatheter arterial chemoembolization refractoriness in hepatocellular carcinoma.

Kazuki Maesaka, Ryotaro Sakamori, Ryoko Yamada, Yuki Tahata, Ayako Urabe, Minoru Shigekawa, Takahiro Kodama, Hayato Hikita, Tomohide Tatsumi, Tetsuo Takehara,

AIM:Intermediate-stage hepatocellular carcinoma (HCC) targeted for transcatheter arterial chemoembolization (TACE) corresponds to a highly heterogeneous population for whom the factors predicting TACE efficacy have not been established. This study aimed to evaluate the impact of hypovascular hepatic nodules coexisting with intermediate-stage HCC as a significant predictive factor for TACE refractoriness. ... Read more >>

Hepatol Res (Hepatology research : the official journal of the Japan Society of Hepatology)
[2020, 50(3):365-373]

Cited: 3 times

View full text PDF listing >>



Successful treatment of drug-induced esophageal ulcer in a patient with chronic heart failure: A case report.

Kazuki Maesaka, Yoshiki Tsujii, Shinichiro Shinzaki, Shunsuke Yoshii, Yoshito Hayashi, Hideki Iijima, Kei Nakamoto, Tomohito Ohtani, Yasushi Sakata, Tetsuo Takehara,

<h4>Rationale</h4>Although esophageal compression due to cardiomegaly may be a risk factor of drug-induced esophageal injuries (DIEIs), the causal relationship between the two conditions has not been fully demonstrated.<h4>Patient concerns</h4>We present a case of a drug-induced esophageal ulcer caused by left atrial enlargement in a 44-year-old woman with end-stage hypertrophic cardiomyopathy. ... Read more >>

Medicine (Baltimore) (Medicine)
[2018, 97(48):e13380]

Cited: 1 time

View full text PDF listing >>





Advertisement


Disclaimer

0.8595 s